BioSpace News Archive

Zomedica Corp. announced that Larry Heaton, Chief Executive Officer, will provide a strategic update and insight into recent acquisitions at the upcoming H.C. Wainwright Global Investment Conference, scheduled for 3:00 pm ET on September 13, 2022.

BioMed Valley Discoveries (BVD) announced that the first patient has been dosed in a phase II clinical trial of ulixertinib (BVD-523) in combination with hydroxychloroquine (HCQ).

Virax Biolabs (“Virax” or the “Company”) (NASDAQ: VRAX), an innovative biotechnology company focused on the prevention, detection, and diagnosis of viral diseases, today announced that Chairman of the Board and Chief Executive Officer, James Foster is presenting at H.C. Wainwright’s 24th Annual Global Investment Conference.

Pretzel Therapeutics, a biotechnology company harnessing the intricacies of mitochondrial biology to develop groundbreaking therapies, launched today with a $72.5 million Series A

Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX) today announced the publication of a preclinical study demonstrating the in vitro and in vivo efficacy of TH1902, an investigational sortilin (SORT1)-targeted peptide-drug conjugate, in inhibiting ovarian cancer and triple-negative breast cancer (TNBC) stem-like cells’ (CSCs) tumor growth.